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Abstract Lipogenic diets that are completely devoid of
methionine and choline (MCD) induce hepatic steatosis.
MCD feeding also provokes systemic weight loss, for unclear
reasons. In this study, we found that MCD feeding causes
profound hepatic suppression of the gene encoding stearoyl-
coenzyme A desaturase-1 (SCD-1), an enzyme whose regula-
tion has significant effects on metabolic rate. Within 7 days of
MCD exposure, hepatic SCD-1 mRNA decreased to nearly
undetectable levels. By day 21, SCD-1 protein was absent from
hepatic microsomes and fatty acids showed a decrease in
monounsaturated species. These changes in hepatic SCD-1
were accompanied by signs of hypermetabolism. Calorimetry
revealed thatMCD-fedmice consumed 37%more energy than
control mice (P5 0.0003). MCD feeding also stimulated fatty
acid oxidation, although fatty oxidation genes were not sig-
nificantly upregulated. Interestingly, despite their increased
metabolic rate, MCD-fed mice did not increase their food
consumption, and as a result, they lost 26% of their body
weight in 21 days. In summary, MCD feeding suppresses
SCD-1 in the liver,which likely contributes to hypermetabolism
and weight loss. MCD feeding also induces hepatic steatosis,
by an independent mechanism. Viewed together, these two
disparate consequences of MCD feeding (weight loss and
hepatic steatosis) give the appearance of an unusual form of
lipodystrophy.—Rizki, G., L. Arnaboldi, B. Gabrielli, J. Yan,
G. S. Lee, R. K. Ng, S. M. Turner, T. M. Badger, R. E. Pitas, and
J. J. Maher.Mice fed a lipogenic methionine-choline-deficient
diet develop hypermetabolism coincident with hepatic sup-
pression of SCD-1. J. Lipid Res. 2006. 47: 2280–2290.
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Elimination of methionine and choline from the diet
causes fat to accumulate rapidly within the liver (1). In this
situation, steatosis is the result of impaired hepatic tri-
glyceride secretion, which in turn is attributable to de-
fective assembly of VLDL (2). Methionine and choline
are important precursors of phosphatidylcholine, the prin-
cipal phospholipid comprising the outer coat of VLDL
particles (3). When these nutrients are in short sup-
ply, VLDL production is impaired and triglycerides accu-
mulate in hepatocytes (2, 4). When a lipogenic substrate
such as sucrose is incorporated into a dietary formula
that lacks methionine and choline, its ability to provoke
hepatic steatosis is accentuated. Lipogenic methionine-
choline-deficient (MCD) formulas induce not only steatosis
but also hepatic inflammation and fibrosis (1, 5, 6). This
severe and progressive liver injury distinguishes the MCD
model of fatty liver from others in which inflammation and
fibrosis are rare (7–10).
Hepatic triglyceride secretion can be blocked by other
means, such as knocking out the gene encoding micro-
somal triglyceride transfer protein (MTP) in a liver-
specific manner. MTP is a peptide that facilitates the
incorporation of triglycerides into VLDL (11); mice that
lack this protein in the liver develop hepatic steatosis. In
liver-specific MTP-deficient mice, fatty liver is associated
with downregulation of the enzyme stearoyl-coenzyme A
desaturase-1 (SCD-1) (12). SCD-1 catalyzes the conversion
of two long-chain fatty acids, palmitate (C16:0) and stea-
rate (C18:0), into their monounsaturated derivatives pal-
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mitoleate (C16:1) and oleate (C18:1) (13). This desatura-
tion step is critical for the incorporation of newly syn-
thesized fatty acids into triglycerides (14). Mice that
completely lack SCD-1 have a reduced capacity for fatty
acid esterification into triglyceride (14). Conversely, they
exhibit enhanced fatty acid catabolism via b-oxidation
(15). The absence of SCD-1 promotes increased energy
expenditure and a lean body habitus despite increased
food consumption (15).
The potential link between inhibition of hepatic tri-
glyceride secretion, suppression of SCD-1, and hyperme-
tabolism is intriguing, because MCD-mediated blockade
of hepatic triglyceride secretion causes weight loss (1).
Based on the mechanistic similarity between MCD feed-
ing and MTP deficiency, we hypothesized that MCD feed-
ing would suppress SCD-1. In addition, based on reports
of enhanced fatty acid oxidation in SCD-1-deficient
mice, we reasoned that MCD-mediated suppression of
SCD-1 would stimulate fatty acid oxidation and increase
oxygen consumption. MCD feeding did indeed down-
regulate SCD-1 and increase fatty acid flux through the
b-oxidation pathway. This resulted in a marked increase
in energy expenditure, which ultimately resulted in
weight loss.
METHODS
MCD feeding
Male C3H/HeOuJ mice (Jackson Laboratory, Bar Harbor, ME)
weighing 23–28 g were used for all studies. Animals were divided
into three groups, each of which received a different dietary
formula for a period of 21 days. One group of mice was fed a high-
sucrose, high-fat diet completely devoid of methionine and cho-
line (MCD) (No. 960439; ICN Biomedicals, Irvine, CA). The MCD
formula comprised 17% protein (as defined amino acids), 65%
carbohydrate (70:30 sucrose-starch), and 10% fat (as corn oil).
The second group of mice was fed a control formula identical to
the MCD formula except that it was supplemented with 3 g/kg
DL-methionine and 2 g/kg choline chloride [methionine-choline-
sufficient (MCS)] (No. 960441; ICN Biomedicals). The third
group of mice was fed standard rodent chow (Laboratory Rodent
Diet 5001; LabDiet, Richmond, IN). The chow diet comprised
23% protein, 56% carbohydrate, and 4.5% fat. While eating the
experimental formulas, all animals had free access to drinking
water. On the final day of the experiment, mice were fasted for 4 h
before euthanasia.
At the time of death, blood was collected from the thoracic
aorta. Serum was separated from cellular elements by centrifu-
gation. Livers were removed, rinsed in ice-cold saline solution,
and divided for various assays as outlined below. All experimental
protocols were approved by the Committee on Animal Research
at the University of California, San Francisco.
Serum chemistries
Serum glucose and alanine aminotransferase were measured
on a BAX autoanalyzer (Bayer Corp., Tokyo, Japan). Leptin and
insulin were measured by ELISA [Quantikine rat/mouse leptin
assay kit (R&D Systems, Minneapolis, MN); mouse insulin ELISA
(Linco, St. Charles, MO)]. Serum cholesterol, triglycerides, and
b-hydroxybutyrate were assayed enzymatically using colorimetric
kits (Boehringer Mannheim GmbH Diagnostica, Montreal,
Canada; Stanbio Laboratory, Boerne, TX).
Measurement of hepatic gene expression by real-time
quantitative PCR
Total RNA was extracted from mouse liver by homogenization
in TRI reagent (Molecular Research Center, Cincinnati, OH)
followed by chloroform extraction and ethanol precipitation.
RNA was incubated with DNase (Qiagen, Inc., Valencia, CA) to
remove contaminating DNA; the enzyme was then inactivated
and removed according to the manufacturer’s specifications
(RNeasy; Qiagen). cDNA was synthesized from 1 mg of RNA in a
reaction mixture containing 2.5 U/ml Moloney murine leukemia
virus reverse transcriptase (Invitrogen, Carlsbad, CA) and 5 mM
random hexamer primers (No. 48190-011; Invitrogen). Real-time
PCR analysis was performed using an ABI Prism 7900 sequence
detection system (Applied Biosystems, Foster City, CA). Assays-
on-Demand (Applied Biosystems) were used to measure all
genes except SCD-1 and acetyl-coenzyme A carboxylase (ACC).
For these, primers and probes were designed using Primer
Express software (version 1.5; Applied Biosystems) (see supple-
mentary Table I). Gene expression was assayed in triplicate by
real-time PCR using a master mix of 5.5 mM MgCl2, 200 mM
deoxynucleoside triphosphates, and 0.5 units of Amplitaq Gold
(Applied Biosystems). Primer and probe concentrations were 500
and 200 nM, respectively, and cDNA was added in an amount
equivalent to 3–5 ng of input RNA. The expression of each test
gene was normalized to that of mouse b-glucuronidase. Quan-
titative detection of specific nucleotide sequences was based on
the fluorogenic 59 nuclease assay (16). Relative gene expression
was calculated using the method of Livak and Schmittgen (17).
Extraction and analysis of hepatic lipids
Samples of fresh liver tissue weighing 100–200 mg were ho-
mogenized in 2 ml of ice-cold methanol containing 0.01% (w/v)
butylated hydroxytoluene (BHT). Homogenates were supple-
mented with 4 ml of chloroform containing 0.01% BHT, and KCl
was added to a final concentration of 50 mM. The solutions were
mixed by vigorous vortexing; they were then centrifuged at 850 g
for 10 min. Organic layers were transferred to fresh test tubes.
Aqueous layers were reextracted with chloroform/BHT; the sec-
ond organic extract from each liver was then pooled with the
first, and the entire sample was dried under a continuous stream
of nitrogen gas. Dried lipid extracts were resuspended in 2:1
chloroform-methanol containing 0.01% BHT (500 ml/100 mg
liver weight). Samples were stored in light-shielded glass contain-
ers at 80jC.
For measurement of total liver cholesterol, aliquots of hepatic
lipid extract were suspended in 1% Triton X-100 and heated
to 50jC before assaying with a commercial kit (Boehringer
Mannheim). Total hepatic phospholipid was determined by hy-
drolyzing lipid extracts and K2HPO4 standards in 0.3 ml of 1 N
H2SO4 at 150jC overnight and decolorizing with hydrogen
peroxide (5% final concentration). Samples and standards were
then supplemented with 0.3 ml of water, 0.1 ml of ascorbic acid
(0.1 g/ml), and 0.6 ml of ammonium molybdate in 1 N H2SO4
(0.01 g/ml). The mixtures were incubated at 55jC for 20 min
and then assayed for color development at 750 nm. Total hepatic
triglyceride was measured chromatographically as described
below. Cholesterol and triglyceride concentrations were expressed
in mg/g liver. Phospholipid concentrations were expressed as
nmol phosphorus/g liver.
FFAs, cholesteryl esters, and triglycerides were separated from
crude hepatic lipid extracts by thin-layer chromatography using
a solvent system of hexane-diethyl ether-acetic acid (80:20:1).
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Bands corresponding to individual lipid fractions were identified
with dichlorofluorescein and verified against known standards
(Nonpolar Lipid Mix B; Matreya, Pleasant Gap, PA). Bands con-
taining triglycerides were scraped from the TLC plate into
separate glass tubes; a known amount of triheptadecanoin was
added as an internal standard, and fatty acid methyl esters were
generated by incubation with 3 N methanolic HCl/toluene (4:1)
for 2 h at 37jC. The methyl esters were then extracted with
hexane-water and analyzed by gas chromatography (HP Chem
Station 6890 Series; Hewlett-Packard, Palo Alto, CA) on a fused
silica capillary column, with polyethylene glycol as the stationary
phase (Alltech ECTMWAX 30 m, 0.25 mm inner diameter, 0.25 mm
film). The relative proportion of individual fatty acids in each
lipid subclass was obtained by integrating the peaks using the HP
Chem Station Standard Integrator Algorithm (Hewlett-Packard).
The total amount of fatty acid in the triglyceride fraction was
calculated by analyzing peak area in comparison with the internal
standard. Similar methods were used to determine the fatty acid
composition of hepatic FFAs (18). FFA analysis was performed by
Lipomics Technologies (West Sacramento, CA).
Preparation of hepatic microsomes
Fresh liver tissue weighing 100–200 mg was homogenized with
a motorized Teflon pestle in 5 volumes of ice-cold 0.25 M sucrose,
50 mM HEPES (pH 7.4), 5 mM DTT, and 13 protease inhibitor
cocktail (HaltTM; Pierce Biotechnology). Crude homogenates
were pelleted by centrifugation at 22,000 g for 10 min, and the
supernatants were subjected to a second round of centrifugation
at 150,000 g for 40 min. Microsomal pellets were suspended in
20% glycerol, 5 mM HEPES (pH 7.4), 5 mM DTT, and 13 pro-
tease inhibitor cocktail. Protein concentration was measured by
the Bradford assay (Bio-Rad, Hercules, CA), and the remainder
of each sample was stored in aliquots at 80jC.
Western blotting
Antibodies directed against AMP-activated protein kinase
(AMPK) and phosphorylated AMPK (threonine 172) were
obtained from Cell Signaling Technology (Beverly, MA). Rabbit
anti-rat SCD-1 antibody was a gift from Dr. Juris Ozols (University
of Connecticut) (19). Liver homogenates or hepatic micro-
somal extracts were separated by electrophoresis through SDS-
polyacrylamide and transferred to polyvinylidene difluoride
membranes. The membranes were blocked for 1 h at room
temperature in Tris-buffered saline containing 5% (w/v) nonfat
dry milk and 0.1% Tween-20. After overnight incubation at 4jC
with primary antibody, the membranes were washed three times
and incubated for 1 h with peroxidase-conjugated goat anti-
rabbit IgG (1:10,000; Cell Signaling Technology). Immunoreac-
tive proteins were detected by chemiluminescence (SuperSignal
West Dura; Pierce Chemical Co.).
De novo lipogenesis
De novo lipogenesis (DNL) was measured by mass isotopomer
distribution analysis as described (20–22). Three days before eu-
thanasia, mice were injected with 0.9% NaCl prepared with 2H2O
(30 ml/kg ip) andmaintained at steady state by administration of
drinking water containing 8% 2H2O. Triglycerides were extracted
from whole liver as described by Jung and colleagues (23) and
derivatized for analysis by GC-MS (Agilent Corp., Palo Alto, CA).
For methyl palmitate, the molecular anion and its isotopes (m/z
270–272, representing M0–M2) were quantified under the se-
lected ion monitoring mode. Calculations were based on 22 pos-
sible sites for deuterium incorporation (24, 25).
Palmitate oxidation and carnitine
palmitoyltransferase activity
Hepatic mitochondria were prepared as described (26), ex-
cept that the buffer used for the initial tissue homogenization
step was supplemented with 2% BSA. Palmitate oxidation was
measured by adding 200 ml of fresh mitochondrial suspension,
corresponding to 250 mg of protein, to 380 ml of a reaction mix-
ture containing 100 mM sucrose, 10 mMTris-HCl, 0.2 mMEDTA,
5 mM KH2PO4, 80 mM KCl, 1 mM MgCl2, 2 mM L-carnitine,
0.1 mMmalate, 2 mM ATP, 0.05 mM CoA, 1 mM DTT, 0.3% fatty
acid-free BSA, and 0.4 mCi of [14C]palmitate (GE Life Sciences,
Piscataway, NY). Incubations were performed for 30 min at 30jC
in screw-capped vials fitted with Teflon sample seals and an
internal well for trapping evolved CO2. Reactions were stopped
by injecting 200 ml of perchloric acid through the Teflon seal into
the reaction mixture and gently mixing with a finger tap. A total
of 200 ml of 1 N NaOH was then injected through the seal into the
internal well to capture CO2 from the atmosphere. One hour after
the reaction was stopped, the vials were opened and the reaction
mixture and NaOH were removed separately. The reaction
mixture was clarified by centrifugation at 10,000 g. Radioactivity
was counted in the supernatant and reported as acid-soluble in-
termediates. Radioactivity trapped in the NaOH fraction was
reported as evolved CO2. All radioactivity measurements were
normalized to mitochondrial protein.
Carnitine palmitoyltransferase-1 (CPT-1) activity was mea-
sured in hepatic mitochondria by the method of Esser and
colleagues (27) using [3H]carnitine (GE Life Sciences) as a sub-
strate. Enzyme activity was expressed as the amount of palmi-
toylcarnitine produced in an 8 min reaction, normalized to
mitochondrial protein.
Indirect calorimetry
Oxygen consumption and carbon dioxide production were
measured in an open-flow indirect calorimeter (Columbus In-
struments, Columbus, OH) as described previously (28). Food
intake and physical activity were measured simultaneously. Data
were collected from three independent experiments, each in-
volving three mice per diet group.
Statistical analysis
All experiments included at least five mice per study group.
Mean data from each study group were compared by ANOVA.
P , 0.05 was considered statistically significant.
RESULTS
Depriving mice of methionine and choline for 21 days
caused a marked reduction in hepatic phospholipid con-
tent (Table 1). This was accompanied by a significant de-
crease in the concentration of serum triglyceride, which
was presumably attributable to a phospholipid-related de-
fect in hepatic triglyceride secretion. Low serum triglyceride
levels in MCD-fed mice were accompanied by reciprocally
high concentrations of hepatic triglyceride; liver weight-
body weight ratios were also high in MCD-fed mice, in-
dicative of steatosis. Liver histology confirmed marked fat
accumulation and demonstrated focal inflammatory infil-
trates (Fig. 1). This coincided with a significant increase in
serum alanine aminotransferase (Table 1). As has been re-
ported previously, MCD feeding provoked significant
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weight loss (1). Adipose tissuemass was markedly decreased
inMCD-fedmice compared with controls, and serum leptin
was also decreased to nearly undetectable levels. This com-
bination of hepatic steatosis and weight loss is reminiscent
of lipodystrophy, but MCD-fed mice lacked any evidence of
insulin resistance, which is a characteristic feature of lipo-
dystrophy syndromes (29).
Examination of liver-specific gene expression in mice
fed the MCD formula for 21 days revealed significant
alterations in several genes related to fatty acid and
triglyceride synthesis (Fig. 2A). Lipogenic genes were
expressed at much lower levels in MCD-fed mice than in
MCS-fed controls; this was true even though both formulas
were equally enriched in sucrose. In general, the lipogenic
gene profile of MCD-fed mice resembled that of chow-fed
mice, with two notable exceptions. MCD feeding suppressed
sterol-regulatory element binding protein-1 (SREBP-1) and
SCD-1 mRNA levels far below even the chow-fed baseline.
SCD-1 mRNA in particular was reduced by 98%, to nearly
undetectable levels. Downregulation of SCD-1 mRNA co-
incided with the disappearance of SCD-1 protein from
hepatic microsomes (Fig. 2B).
Investigation of the kinetics of SCD-1 gene regulation
revealed that MCD feeding initially induced SCD-1 mRNA
expression in the liver (Fig. 2C). SCD-1 mRNA increased
by 4-fold during the first 24 h of MCD feeding; imme-
diately thereafter, it began to decline, decreasing to less
than normal by day 4. By contrast, MCS feeding caused an
8-fold increase in SCD-1 mRNA at 24 h that was sustained
for 21 days. In MCD-fed mice, the disappearance of SCD-1
mRNA exhibited first-order kinetics (Fig. 2D) with a pre-
dicted half-life of 45 h. This suggests that SCD-1 gene
transcription ceased very soon after the introduction of the
MCD formula.
To assess the impact of these diet-induced changes in
gene expression on hepatic lipid metabolism, we mea-
sured DNL in the livers of mice fed MCD and control
formulas for 21 days. As expected, both fractional and
absolute DNL were greatest in mice fed the sucrose-rich
MCS control formula (Table 2). In chow-fed controls,
fractional DNL was high but absolute DNL was not; this
reflected the low hepatic lipid content of chow-fed ani-
mals. In MCDmice, fractional DNL was quite low. This was
likely attributable to the large pool of unlabeled lipid that
had already accumulated in MCD livers before the intro-
duction of the metabolic tracer. Absolute DNL inMCD-fed
mice was intermediate between chow-fed and MCS con-
trols, indicating that these mice retained some capacity for
palmitate synthesis as predicted by their expression of ATP
citrate lyase, acyl-CoA carboxylase, and fatty acid synthase
(Fig. 2A).
MCD feeding altered the fatty acid composition of he-
patic lipids in a manner commensurate with low SCD-1
activity. Specifically, MCD feeding provoked a 2- to 3-fold
increase in the ratio of saturated to monounsaturated
long-chain fatty acids in the liver in the triglyceride frac-
tion (Table 3) as well as in hepatic free fatty acids (data not
shown). Reduced desaturase activity was also reflected in
the absolute amounts of saturated and monounsaturated
long-chain fatty acids in the livers of MCD mice. In MCD-
fed livers, saturated long-chain fatty acids exceeded
monounsaturated fatty acids by 30%, whereas in chow-
fed and MCS livers, the two species were equivalent
(Fig. 3).
The diet-induced suppression of SCD-1 in MCD-fed
mice was accompanied by evidence of hypermetabolism.
After only 8 days of MCD feeding, MCD mice displayed
a 37% increase in energy expenditure relative to MCS
controls (P 5 0.0003) (Fig. 4A). MCD-fed mice were not
hyperthermic (MCD, 37.6 6 0.3jC; MCS, 37.9 6 0.3jC);
they did, however, display a tendency to be more active
than MCS-fed mice during nocturnal periods (25% in-
crease) (Fig. 4B). MCD-fed mice also consumed nearly
four times as much water as MCS controls (P 5 0.001)
TABLE1. Clinical characteristics of mice after 21 days on experimental diets
Dietary Group
Characteristic Chow MCS MCD
Body weight (g) 30.2 6 0.8 38.2 6 0.4a 19.6 6 0.2b,c
Liver weight (g) 1.39 6 0.03 1.71 6 0.03a 0.98 6 0.03b,c
Adipose weight (g) 1.5 6 0.2 4.9 6 0.2a 0.3 6 0.1b,c
Liver weight-body weight (%) 4.8 6 0.1 4.6 6 0.0 5.1 6 0.1b,c
Adipose weight-body weight (%) 4.9 6 0.4 13.1 6 0.6a 1.61 6 0.4b,c
Serum triglyceride (mg/dl) 120.5 6 27.8 122.9 6 32.8 46.4 6 3.4b,c
Serum cholesterol (mg/dl) 104.5 6 3.3 145.5 6 6.7a 77.2 6 6.2b,c
Serum alanine aminotransferase (IU/l) 79.75 6 1.65 82.0 6 2.7 320.4 6 57.9b,c
Serum glucose (mg/dl) 245.2 6 11.6 219.2 6 21.0 148.8 6 10.8b,c
Serum insulin (ng/ml) 0.87 6 0.33 1.02 6 0.14 0.41 6 0.09c
Serum leptin (ng/ml) ND 13.9 6 1.2 0.6 6 0.1c
Serum b-hydroxybutyrate (mg/dl) 3.3 6 0.4 5.1 6 1.1 10.6 6 1.2b,c
Hepatic phospholipid (nmol/mg protein) 379.2 6 10.4 434.5 6 14.6 363.4 6 14.9b,c
Hepatic triglyceride (mg/mg protein) 21.2 6 2.3 136.6 6 23.5a 815.8 6 60.2b,c
Hepatic cholesterol (mg/mg protein) 24.5 6 0.8 31.0 6 1.3 21.8 6 3.6b,c
MCD, high-sucrose diet devoid of methionine and choline; MCS, high-sucrose diet supplemented with
methionine and choline; ND, not determined. Values represent means 6 SEM for n 5 5.
a P , 0.05 for MCS versus chow.
b P , 0.05 for MCD versus chow.
c P , 0.05 for MCD versus MCS.
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(Fig. 4C), despite normoglycemia (Table 1). Notably, MCD-
fed mice did not consume any more food than control
mice (Fig. 4D). As a result, they lost a significant amount of
weight over 21 days (Fig. 4E).
In scd-1/ mice, hypermetabolism has been attributed
to enhanced b-oxidation of fatty acids (15). In these mice,
fatty acid oxidation is upregulated at the level of gene
expression in conjunction with the activation of AMPK
(30, 31). MCD mice also displayed evidence of increased
fatty acid oxidation, based on their development of
ketonemia after a 4-h fast (Table 1). Unlike scd-1/ mice,
however, MCD-fed mice showed no induction of genes
controlling fatty acid oxidation (Fig. 5A) and no increase in
AMPK phosphorylation relative to control mice (Fig. 5B).
When palmitate oxidation was measured directly in hepatic
mitochondria from MCD-fed mice, it was 33% higher than
that in MCS controls, but the difference did not reach
statistical significance (Fig. 5C). CPT-1 activity, also
measured in isolated mitochondria, was no different be-
tween the two groups of mice (Fig. 5D). Together, these
data suggest that the ketonemia observed in MCD-fed
mice in vivo results from an increased flux of fatty acids
through the b-oxidation pathway rather than from in-
trinsic upregulation of the oxidative enzymes themselves.
The concept of accentuated fatty acid flux through he-
patic mitochondria in MCD mice is strengthened by the
fact that MCD feeding significantly induced the hepatic
expression of uncoupling protein-2 (Fig. 5E). Uncou-
pling protein-2 induction, in turn, was accompanied by a
marked decrease in hepatic ATP levels in MCD-fed mice
(1.34 6 0.02 vs. 0.37 6 0.01 mmol/g in MCS vs. MCD,
respectively; P , 0.001).
DISCUSSION
The current study shows that methionine and choline
deprivation has pronounced effects on hepatic lipid me-
tabolism that go beyond the inhibition of triglyceride se-
cretion. Specifically, MCD feeding profoundly suppresses
SCD-1 gene expression and activity in the liver and to a
lesser extent blunts hepatic lipogenesis. Coincident with
SCD-1 suppression, MCD feeding causes hypermetabo-
lism, as demonstrated by increased total body energy ex-
penditure, enhanced fatty acid oxidation, and uncoupling
of hepatic mitochondria. These derangements are attrib-
utable at lease in part to low SCD-1 activity, because mice
with targeted disruption of the SCD-1 gene display a simi-
lar phenotype (15, 31).
MCD feeding has become popular in recent years as a
model of hepatic steatosis and steatohepatitis. The fact
that MCD-mediated fatty liver was accompanied by a
downregulation of hepatic SCD-1 is unusual, because most
other models of fatty liver are characterized by significant
induction of this enzyme (32–35). MCD feeding initially
induced SCD-1, as would be expected in response to a
sucrose-rich diet (36); however, the increase was much less
robust and more transient than that in control mice
(Fig. 2C). This rapid increase and decline in hepatic SCD-1
mRNA in MCD-fed mice gave the appearance of a nega-
tive feedback response. What might be triggering rapid
feedback regulation of SCD-1 in this animal model is un-
certain, because SCD-1 is not subject to end-product inhi-
bition by monounsaturated fatty acids (37). PUFAs may be
responsible, because they can suppress SCD-1 gene expres-
sion (37, 38). Our data indicate that PUFAs accumulated
disproportionately in the livers of MCD-fed mice com-
pared with MCS controls. A similar disproportionate in-
crease in hepatic PUFAs was noted previously in mice with
liver-specific MTP deficiency (12). Both animals experi-
ence suppression of SCD-1, which suggests that the in-
ability to mobilize hepatic triglyceride causes unique
alterations in hepatic fatty acid composition that signifi-
cantly affect SCD-1 expression and activity.
Fig. 1. Liver histology and serum alanine aminotransferase in mice
fed methionine-choline-deficient (MCD) or control formulas.
Photomicrographs show hematoxylin and eosin-stained sections of
liver tissue from mice fed standard chow, the methionine-choline-
sufficient (MCS) formula, or theMCD formula for 21 days. Histology
in the chow and MCS livers appears normal. The MCD liver shows
marked steatosis with focal aggregates of inflammatory cells.
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The decline in SCD-1 expression that occurred in re-
sponse to MCD feeding was likely a key event in the evolu-
tion of other metabolic abnormalities. For example, with
the loss of SCD-1 mRNA from the liver, the expression of
upstream lipogenic genes was reduced significantly, caus-
ing a relative decrease in hepatic lipogenesis well below
that expected for mice ingesting a sucrose-rich diet. Down-
regulation of lipogenic gene expression in MCD-fed mice
could be attributable in part to the MCD-mediated sup-
pression of SREBP-1 mRNA, which regulates a number of
target genes involved in the lipogenic pathway; it is impor-
tant to note, however, that SCD-1 also has significant effects
on lipogenic gene expression independent of SREBP-1
(39). Despite profound SCD-1 suppression, MCD-fed mice
retained some capacity for hepatic triglyceride synthesis,
as shown by their ability to incorporate newly synthesized
Fig. 2. Changes in hepatic gene and protein expression induced by MCD and control formulas. A: Histograms show the relative
abundance of mRNA encoding several lipogenic genes in the livers of mice fed MCD or control formulas for 21 days. mRNA abundance was
assessed by quantitative PCR as described in Methods; data were normalized to the expression of mouse b-glucuronidase as an internal
control. ACC1, acetyl-coenzyme A carboxylase-1; ACLY, ATP citrate lyase; GPAT, glycerol phosphate acyltransferase; SCD-1, stearoyl-
coenzyme A desaturase-1; SREBP-1, sterol-regulatory element binding protein-1. Values represent means 6 SEM for n 5 5. a P , 0.05 for
MCS versus chow; b P , 0.05 for MCD versus chow; c P , 0.05 for MCD versus MCS. B: Immunoblot depicting SCD-1 protein in liver
microsomes from mice fed chow (C), the MCS formula, or the MCD formula for 21 days. CTRL, control. C: Histogram depicting the time
course of hepatic SCD-1 mRNA regulation in mice fed the MCD or MCS formula. Values represent means 6 SEM for n 5 5. D: Graph
depicting the kinetics of SCD-1 mRNA disappearance in MCD-fed mice from days 1–14.
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palmitate into triacylglycerol (Table 2). This is at odds
with prior assertions that SCD-1 is essential for triglyc-
eride production (14). It is possible that SCD-1 must be
completely absent to block triglyceride synthesis, as in
scd-1/mice, whereas in MCD-fed mice, the 2% of SCD-1
mRNA that persisted in the liver was sufficient to support
this activity.
SCD-1 suppression in MCD-fed mice was accompanied
by hypermetabolism, as it is in scd-1/ mice (14, 15). In
MCD mice, as in scd-1/ mice, hypermetabolism was as-
sociated with an increase in fatty acid oxidation in vivo
(31). scd-1/ mice are believed to upregulate fatty acid
b-oxidation to compensate for their reduced ability to
channel fatty acids to esterification; in these animals,
b-oxidation is induced at the transcriptional level via AMPK
(30, 31). In MCD-fed mice, however, fatty acid b-oxidation
was enhanced without any evidence of gene induction or
AMPK activation. The failure of MCD feeding to induce
the expression of b-oxidation genes despite extremely low
levels of SCD-1 may be attributable to the high concentra-
tion of fatty acids present in MCD livers. Indeed, recent
studies indicate that intracellular fatty acids can interfere
with an otherwise strong stimulus to AMPK activation (40)
by means of long-chain acyl-CoA ester interference with
the phosphorylation of the AMPK kinase complex, LKB1/
STRAD/MO25 (41). Because AMPK is not activated in the
livers of MCD-fed mice, another mechanism must be re-
sponsible for the increase in fatty acid oxidation observed
in vivo in response to MCD feeding. Fatty acids are capable
TABLE2. DNL in mice fed MCD and control formulas for 21 days
DNL Chow MCS MCD
Fractional DNL (%) 71.3 6 1.8 81.8 6 1.3a 34.0 6 3.8c,d
Absolute DNL (mg/liver) 1.4 6 0.0 14.5 6 0.3b 8.1 6 0.6c,d
DNL, de novo lipogenesis. Mice were fed experimental formulas
for a total of 21 days. Three days before the end of the study (day 19),
mice were given a loading dose of deuterated saline (30 ml/kg ip) and
placed on drinking water containing 8% 2H2O. At the end of the 3 day
labeling period, mice were euthanized and livers removed for the mea-
surement of DNL as described in Methods. Fractional DNL represents
the proportion of palmitate molecules in the triglyceride fraction
that were labeled with deuterium. Absolute DNL represents the total
amount of deuterated palmitate present in the liver. Treatment groups
were as in Table 1. Values represent means 6 SEM for n 5 4.
a P , 0.01 for MCS versus chow.
b P , 0.0001 for MCS versus chow.
c P , 0.0001 for MCD versus chow.
d P , 0.0001 for MCD versus MCS.
Fig. 3. Saturated and monounsaturated fatty acids in the livers
of mice fed MCD and control formulas. Histograms depict the
absolute amounts of long-chain saturated (C16:0 1 C18:0) and
monounsaturated (C16:1 1 C18:1) fatty acids present in hepatic
triglycerides after 21 days on experimental diets. Values represent
means 6 SEM for n 5 5. * P 5 0.002 for MCD versus MCS.
TABLE3. Fatty acid composition of hepatic triglycerides
Composition
Fatty Acid Chow MCS MCD
% of total
Myristic, 14:0 1.06 6 0.08 1.68 6 0.25 1.38 6 0.10
Palmitic, 16:0 36.21 6 1.78 33.98 6 0.98 25.49 6 0.70b,c
Palmitoleic, 16:1 4.59 6 0.15 4.67 6 0.46 1.59 6 0.11b,c
Stearic, 18:0 1.97 6 0.17 1.66 6 0.10 4.51 6 0.17b,c
Oleic, 18:1 27.23 6 1.41 25.18 6 0.99 19.28 6 0.39b,c
Linoleic, 18:2n6 17.76 6 1.14 25.94 6 1.62a 29.71 6 0.68b
g-Linolenic, 18:3n6 0.92 6 0.26 0.72 6 0.07 2.46 6 0.09b,c
Eicosenoic, 20:1 1.98 6 0.20 0.84 6 0.04a 0.73 6 0.03b
Eicosadienoic, 20:2n6 0.90 6 0.06 0.76 6 0.06 0.81 6 0.01
Eicosatrienoic, 20:3n6 0.90 6 0.09 1.04 6 0.14 1.93 6 0.06b,c
Arachidonic, 20:4n6 0.91 6 0.08 1.60 6 0.25a 5.63 6 0.22b,c
Docosatetraenoic, 22:4 0.54 6 0.11 0.62 6 0.10 1.80 6 0.10b,c
Docosahexaenoic, 22:6 4.52 6 0.52 1.32 6 0.35a 4.67 6 0.36c
Total 100.00 100.00 100.00
16:0/16:1 7.9 7.2 15.9
18:0/18:1 0.07 0.07 0.23
Treatment groups were as in Table 1. Values represent means 6 SEM for n 5 5.
a P , 0.05 for MCS versus chow.
b P , 0.05 for MCD versus chow.
c P , 0.05 for MCD versus MCS.
2286 Journal of Lipid Research Volume 47, 2006
 at Polo Library, on April 22, 2011
w
w
w
.jlr.org
D
ow
nloaded from
 
0.DC1.html 
http://www.jlr.org/content/suppl/2006/07/10/M600198-JLR20
Supplemental Material can be found at:
of facilitating their own entry into mitochondria by reduc-
ing the malonyl-CoA-mediated inhibition of CPT-1 (42).
Although at low fatty acid concentrations this appears to
occur through AMPK-mediated phosphorylation and inac-
tivation of ACC (43), at higher concentrations fatty acids
inhibit ACC directly via allosteric interaction (44). This
offers an explanation for why fatty acid flux through the
b-oxidation pathway is apparently increased in MCD-fed
mice without a significant change in oxidative enzyme ex-
pression or enzyme activity in an in vitro assay.
SCD-1-null mice compensate for their hypermetabolic
state by significantly increasing their caloric intake. No-
tably, MCD-fed mice did not increase their food consump-
tion as their energy expenditure increased, and thus they
lost a significant amount of weight. This imbalance be-
tween energy expenditure and fuel consumption indicates
that MCD-fed mice were incorrectly sensing their nutri-
tional status. Several factors were present in MCD mice
that should have prompted increased food intake: low
circulating lipids, low serum glucose, low insulin levels,
and extremely low leptin levels. Why these were ineffective
is uncertain, but it is tempting to speculate that fatty acids
are again responsible. Circulating long-chain fatty acids
curtail food intake by signaling the hypothalamus that the
body is in a state of nutritional surplus (45). The accu-
mulation of intracellular long-chain fatty acids within the
hypothalamus has a similar effect (46). Although MCD-fed
mice do not have increased circulating lipids, they may
have high intracellular concentrations of long-chain fatty
acids in the brain for the same reason that they do in the
liver. Studies are under way to address this question.
Although our data indicate that hypermetabolism in
MCD-fed mice is closely linked to the hepatic suppression
of SCD-1, these mice began to lose weight before hepatic
Fig. 4. Energy expenditure, water and food consumption, and body weight in mice fed MCD and control formulas. A–D: Histograms de-
pict energy expenditure (A), physical activity (B), water consumption (C), and food consumption (D) in mice fed chow, MCD, or MCS
formulas for 8 days. Measurements were obtained over a 24 h period from day 8 to day 9 on the experimental formulas. Values represent
means 6 SEM for n 5 9. a P , 0.05 for MCS versus chow; b P , 0.05 for MCD versus chow. E: Graph illustrating body weight in mice fed
chow, MCS, and MCD formulas for 21 days. Values represent means 6 SEM for n 5 5.
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SCD-1 mRNA decreased significantly below normal. This
suggests that other factors are also at play in the patho-
genesis of MCD-mediated weight loss. Liver injury could
contribute to weight loss; this is unlikely, however, because
MCD-mediated steatohepatitis is completely preventable by
drug treatment without any concomitant improvement in
weight loss (47). Muscle is an important contributor to total
body energy expenditure, particularly during periods of
activity (48). MCD feeding probably influences SCD-1 in
this tissue as it does in liver, perhaps with even more rapid
kinetics. Further exploration of the effect of MCD feeding
on extrahepatic organs will be informative.
Noteworthy in our study is that MCD-mediated down-
regulation of SCD-1 did not alleviate hepatic steatosis.
At face value, this appears paradoxical, because SCD-1
suppression markedly improves steatosis in other experi-
mental models of fatty liver (33, 49) and SCD-1 antagonists
are under development as treatments for hepatic steatosis
and obesity (50, 51). In fatty liver caused by leptin defi-
ciency or lipoatrophy, however, the cellular machinery for
exporting hepatic triglyceride is intact. Thus, augmenting
hepatic fat disposal by inhibiting SCD-1 significantly re-
duces the amount of fat retained within the liver. MCD-fed
mice, by contrast, have marked impairment of hepatic tri-
Fig. 5. Fatty acid oxidation in mice fed MCD and control formulas. A: Histogram depicting the relative abundance of genes pertinent to
fatty acid oxidation in the livers of chow-, MCS-, or MCD-fed mice. Values represent means6 SEM for n5 5. ACO, acyl-coenzyme A oxidase;
AMPK, AMP-activated protein kinase; BFP, bifunctional protein; CPT-1, carnitine palmitoyltransferase-1; PGC-1a/b, peroxisome proliferator-
activated receptor-g coactivator-1a/b; PPARa, peroxisome proliferator-activated receptor a; TFP, trifunctional protein; Thiol B, thiolase B;
VLAD, very long chain acyl dehydrogenase. B: Western blot illustrating AMPK and phospho-AMPK (P-AMPK) in the livers of mice fed
MCD and MCS formulas for 21 days. C: Histogram showing the conversion of radiolabeled palmitate by hepatic mitochondria isolated from
MCS- or MCD-fed mice to acid-soluble intermediates (ASM) and CO2. Values represent means 6 SEM (for total cpm) for n 5 6. D: Graph
showing CPT-1 activity measured as described in Methods in hepatic mitochondria fromMCS- or MCD-fed mice. Values represent means6
SEM for n5 3. E: Histogram demonstrating uncoupling protein-2 (UCP-2) mRNA expression in the livers of mice fed chow, MCS, or MCD
formulas for 21 days. Values represent means6 SEM for n5 5. a P, 0.05 for MCS versus chow; b P, 0.05 for MCD versus chow; c P, 0.05
for MCD versus MCS.
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glyceride secretion. In these animals, the degree to which
SCD-1 suppression facilitated hepatic fat disposal was
clearly inadequate to compensate for their defect in tri-
glyceride export. This suggests that humans with hepatic
steatosis attributable to impaired hepatic triglyceride se-
cretion, such as those with MTP polymorphisms (52, 53),
would not benefit from SCD-1 inhibition.
In summary, inhibiting hepatic triglyceride secretion by
feeding mice a diet completely devoid of methionine and
choline provokes a profound suppression of SCD-1 in the
liver. SCD-1 suppression is likely a compensatory mecha-
nism, designed to reduce lipid synthesis and enhance lipid
oxidation under conditions in which triglyceride export is
inactive. Because the MCD formula is rich in sucrose, DNL
continues despite efforts at downregulation; this exacer-
bates the hepatic lipid accumulation prompted initially by
VLDL secretion blockade. The movement of hepatic fatty
acids through the b-oxidation pathway is increased inMCD-
fed mice, which in turn increases total body energy expen-
diture and promotes mitochondrial uncoupling. These
changes are not offset by increased food intake, for reasons
that are unclear. The net result of these metabolic derange-
ments is a unique form of lipodystrophy, with significant
weight loss in combination with hepatic steatosis.
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